1997:HKEXBioInfra Co., Ltd. Analysis
Data as of 2026-07-29 - not real-time
₩1,879.00
Latest Price
8/10Risk
Risk Level: High
Executive Summary
BioInfra’s share price of 1,879 KRW sits well below its 20‑day (1,994 KRW), 50‑day (2,692 KRW) and 200‑day (4,029 KRW) moving averages, confirming a bearish technical backdrop despite a modestly bullish MACD histogram and an RSI hovering around 60. Volume is on an upward trend, but the stock is trading near its identified support at 1,500 KRW and far from the resistance ceiling of 2,665 KRW, suggesting limited upside in the near term.
Fundamentally, the company is struggling: revenue growth is a tepid 1 %, operating and profit margins are deep in the negatives (‑44 % and ‑43 % respectively), and cash flow is negative while debt exceeds equity (debt‑to‑equity ≈ 101 %). The dividend yield appears attractive at 11.34 % but the payout ratio of over 220 % is clearly unsustainable. High 30‑day volatility (≈147 %) and a historic drawdown of 73 % amplify the risk, even as the broader market sentiment is in “Extreme Greed” mode.
Fundamentally, the company is struggling: revenue growth is a tepid 1 %, operating and profit margins are deep in the negatives (‑44 % and ‑43 % respectively), and cash flow is negative while debt exceeds equity (debt‑to‑equity ≈ 101 %). The dividend yield appears attractive at 11.34 % but the payout ratio of over 220 % is clearly unsustainable. High 30‑day volatility (≈147 %) and a historic drawdown of 73 % amplify the risk, even as the broader market sentiment is in “Extreme Greed” mode.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Price below all major moving averages
- High volatility and recent 73% drawdown
- Unsustainable dividend payout
Medium Term
1–3 yearsCautious
Model confidence: 5/10
Key Factors
- Persistent operating losses and negative cash flow
- Debt level exceeding equity
- Regulatory exposure inherent to CRO business
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Potential sector consolidation could improve fundamentals
- Low beta suggests limited systematic risk over time
- Need for a credible turnaround plan to restore profitability
Key Metrics & Analysis
Financial Health
Revenue Growth1.10%
Profit Margin-42.60%
ROE-54.29%
ROA-10.72%
Debt/Equity101.28
Op. Cash Flow₩-808735296
Free Cash Flow₩-221206064
Industry P/E29.9
Technical Analysis
TrendBearish
RSI60.4
Support₩1,500.00
Resistance₩2,665.00
MA 20₩1,993.50
MA 50₩2,691.90
MA 200₩4,028.50
MACDBullish
VolumeIncreasing
Fear & Greed Index85.91
Valuation
GradeOvervalued
TypeValue
Dividend Yield11.34%
Risk Assessment
Beta0.68
Volatility147.40%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.